| 1 |
Magalhães D, Dos Santos J, Frutuoso A, Mesquita A. Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Cureus 2023;15:e34724. [PMID: 36909127 DOI: 10.7759/cureus.34724] [Reference Citation Analysis]
|
| 2 |
Fan HL, Hsieh CB, Kuo SM, Chen TW. Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients. World J Gastrointest Surg 2022; 14(9): 930-939 [DOI: 10.4240/wjgs.v14.i9.930] [Reference Citation Analysis]
|
| 3 |
Bai L, Yang Z, Liu J, Wang D, Yu H, Wang F. Prognostic Significance of CCDC137 Expression and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/5638675] [Reference Citation Analysis]
|
| 4 |
Ahmed O, Vachharajani N, Croome KP, Tabrizian P, Agopian V, Halazun K, Hong JC, Dageforde LA, Chapman WC, Doyle MM; Primary Liver Tumor Study Group. Are Current National Review Board Downstaging Protocols for Hepatocellular Carcinoma Too Restrictive? J Am Coll Surg 2022;234:579-88. [PMID: 35290278 DOI: 10.1097/XCS.0000000000000140] [Reference Citation Analysis]
|
| 5 |
Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Carissimi F, Barbaglia MN, Salmi L, Ciulli C, Roccamatisi L, Cordaro G, Mallela VR, Minisini R, Leone BE, Donadon M, Torzilli G, Pirisi M, Romano F, Famularo S. Finding the seed of recurrence: Hepatocellular carcinoma circulating tumor cells and their potential to drive the surgical treatment. World J Gastrointest Surg 2021; 13(9): 967-978 [PMID: 34621473 DOI: 10.4240/wjgs.v13.i9.967] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Mahn R, Sadeghlar F, Bartels A, Zhou T, Weismüller T, Kupczyk P, Meyer C, Gaertner FC, Toma M, Vilz T, Knipper P, Glowka T, Manekeller S, Kalff J, Strassburg CP, Gonzalez-Carmona MA. Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes. Medicine (Baltimore) 2021;100:e27082. [PMID: 34559100 DOI: 10.1097/MD.0000000000027082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1617. [PMID: 33807392 DOI: 10.3390/cancers13071617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 10 |
Lee S, Kim KW, Jeong WK, Jeong SY, Hwang JA, Choi JS, Lee SG, Joh JW. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study. Ann Surg Oncol 2021. [PMID: 33751296 DOI: 10.1245/s10434-021-09772-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Song K, He F, Xin Y, Guan G, Huo J, Zhu Q, Fan N, Guo Y, Zang Y, Wu L. TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy. Pharmgenomics Pers Med 2021;14:269-78. [PMID: 33623416 DOI: 10.2147/PGPM.S294307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Liu Z, Ding F, Shen X. Total flavonoids of Radix Tetrastigma suppress inflammation-related hepatocellular carcinoma cell metastasis. Mol Genet Genomics 2021;296:571-9. [PMID: 33576897 DOI: 10.1007/s00438-020-01759-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 13 |
Wang G, Bai X, Jiang G, Jin S, Wang Q, Wang A, Peng R, Ke A, Bai D. GIT1 overexpression promotes epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. Bioengineered 2021;12:30-43. [PMID: 33258389 DOI: 10.1080/21655979.2020.1855914] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 14 |
Wang Z, Zhang N, Lv J, Ma C, Gu J, Du Y, Qiu Y, Zhang Z, Li M, Jiang Y, Zhao J, Du H, Zhang Z, Lu W, Zhang Y. A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. Biomed Res Int 2020;2020:4037639. [PMID: 33163533 DOI: 10.1155/2020/4037639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 16 |
Zhang YL, Nie CH, Chen F, Zhou TY, Zhou GH, Zhu TY, Chen SQ, Chen XH, Wang HL, Wang BQ, Yu ZN, Jing L, He ZM, Sun JH. Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2020;10:1754. [PMID: 32984060 DOI: 10.3389/fonc.2020.01754] [Reference Citation Analysis]
|
| 17 |
Li H, Wei N, Ma Y, Wang X, Zhang Z, Zheng S, Yu X, Liu S, He L. Integrative module analysis of HCC gene expression landscapes. Exp Ther Med 2020;19:1779-88. [PMID: 32104233 DOI: 10.3892/etm.2020.8437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 18 |
Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 19 |
Olisov OD, Dzhanyan IA, Novruzbekov MS, Breder VV, Ilinskiy ME, Zimina LN, Moroz EA, Laktionov KK, Guliaev VA, Lutsyk KN, Magomedov KM. Multidisciplinary approach in hepatocellular carcinoma progression treatment after liver transplantation: the first experience in Russia. Ann hir gepatol 2019;24:65-73. [DOI: 10.16931/1995-5464.2019465-73] [Reference Citation Analysis]
|
| 20 |
Han B, Huang J, Yang Z, Zhang J, Wang X, Xu N, Meng H, Wu J, Huang Q, Yang X, Shen R, Sun C. miR-449a Is Related to Short-Term Recurrence of Hepatocellular Carcinoma and Inhibits Migration and Invasion by Targeting Notch1. Onco Targets Ther 2019;12:10975-87. [PMID: 31853185 DOI: 10.2147/OTT.S216997] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Chao JS, Zhao SL, Ou-yang SW, Qian YB, Liu AQ, Tang HM, Zhong L, Peng ZH, Xu JM, Sun HC. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation. World J Gastroenterol 2019; 25(37): 5630-5640 [PMID: 31602163 DOI: 10.3748/wjg.v25.i37.5630] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Hong SK, Lee K, Yoon KC, Kim H, Ahn S, Kim H, Lee J, Cho J, Yi N, Suh K. Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 23 |
Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 57] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 24 |
Ho CM, Chen HL, Hu RH, Lee PH. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Ther Adv Med Oncol 2019;11:1758835919843463. [PMID: 31065295 DOI: 10.1177/1758835919843463] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 25 |
Jiang C, Liu X, Wang M, Lv G, Wang G. High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD1)-Mediated Function of T Cells. Oncol Res 2019;27:1025-34. [PMID: 30982498 DOI: 10.3727/096504018X15456687424096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 26 |
Shi JH, Guo WZ, Jin Y, Zhang HP, Pang C, Li J, Line PD, Zhang SJ. Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence. Cancer Med 2019;8:1269-78. [PMID: 30714677 DOI: 10.1002/cam4.2006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 27 |
Bao J, Chen X, Hou Y, Kang G, Li Q, Xu Y. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway. Biomedicine & Pharmacotherapy 2018;107:824-33. [DOI: 10.1016/j.biopha.2018.08.079] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 28 |
Zhang R, Zhang LJ, Yang ML, Huang LS, Chen G, Feng ZB. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol Med Rep 2018;17:2211-28. [PMID: 29207133 DOI: 10.3892/mmr.2017.8167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 29 |
Hamilton EC, Balogh J, Nguyen DT, Graviss EA, Heczey AA, Austin MT. Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience. J Pediatr Surg 2017:S0022-3468(17)30657-7. [PMID: 29108844 DOI: 10.1016/j.jpedsurg.2017.10.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 30 |
Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget 2017;8:107237-57. [PMID: 29291025 DOI: 10.18632/oncotarget.20883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 31 |
Yang E, Li X, Jin N. The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment. Cancer Cell Int 2016;16:80. [PMID: 27752239 DOI: 10.1186/s12935-016-0351-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 32 |
Zhang Y, Zhang X, Zhang J, Sun B, Zheng L, Li J, Liu S, Sui G, Yin Z. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. Cancer Biol Ther 2016;17:1177-87. [PMID: 27662377 DOI: 10.1080/15384047.2016.1235665] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 33 |
Budhu A, Wang XW. Molecular Profiling of Human Hepatocellular Carcinoma. Hepatocellular Carcinoma 2016. [DOI: 10.1007/978-3-319-34214-6_5] [Reference Citation Analysis]
|
| 34 |
Sacco R, Antonucci M, Bresci G, Corti A, Giacomelli L, Mismas V, Rainieri M, Romano A, Eggenhoffner R, Tumino E, Cabibbo G. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Review of Anticancer Therapy 2016;16:169-75. [DOI: 10.1586/14737140.2016.1123625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 35 |
Wu X, Deng L, Tang D, Ying G, Yao X, Liu F, Liang G. miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma. Tumour Biol 2016;37:6813-21. [PMID: 26662310 DOI: 10.1007/s13277-015-4506-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 36 |
Hsueh KC, Lee TY, Kor CT, Chen TM, Chang TM, Yang SF, Hsieh CB. The role of liver transplantation or resection for patients with early hepatocellular carcinoma. Tumour Biol. 2016;37:4193-4201. [PMID: 26490991 DOI: 10.1007/s13277-015-4243-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
